Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126364101 | 12636410 | 1 | I | 201509 | 20160725 | 20160809 | 20160809 | EXP | JP-ACCORD-042972 | ACCORD | KIBA T, SAITO Y, OTOMO C, SATO M, MEGURO T. [A PANCREATIC CANCER PATIENT IN WHOM PEGFILGRASTIM PROPHYLAXIS DID NOT PREVENT SEVERE NEUTROPENIA CAUSED BY THE FOLFIRINOX REGIMEN]. GAN TO KAGAKU RYOHO. 2016 JUL;43(7):913-5. | 62.00 | YR | M | Y | 0.00000 | 20160809 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126364101 | 12636410 | 1 | PS | FLUOROURACIL. | FLUOROURACIL | 1 | (BOLUS) 400 MG/M2, (CONTINUOUS INFUSION) 2,400 MG/M2 WAS INITIATED IN THE STANDARD THERAPEUTIC DOSE | Y | 40743 | 2400 | MG/M**2 | ||||||||
| 126364101 | 12636410 | 2 | SS | GEMCITABINE/GEMCITABINE HYDROCHLORIDE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | 14 COURSES WAS PERFORMED | U | 91594 | 1000 | MG/M**2 | ||||||||
| 126364101 | 12636410 | 3 | SS | IRINOTECAN | IRINOTECAN | 1 | DOSE ADMITTED 65% DOSE AS 150 MG/BODY | Y | 79068 | ||||||||||
| 126364101 | 12636410 | 4 | SS | OXALIPLATIN. | OXALIPLATIN | 1 | 65% OF DOSE AS 85MG/BODY, | Y | 0 | ||||||||||
| 126364101 | 12636410 | 5 | SS | CALCIUM LEVOFOLINATE | LEVOLEUCOVORIN CALCIUM | 1 | Y | 0 | 200 | MG/M**2 | |||||||||
| 126364101 | 12636410 | 6 | SS | PACLITAXEL/PACLITAXEL LIPOSOME | PACLITAXEL | 1 | 3 WEEKS ADMINISTRATION WITH 1 WEEK REST DRUG??NAB-PACLITAXEL | U | 0 | 125 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126364101 | 12636410 | 1 | Pancreatic carcinoma |
| 126364101 | 12636410 | 2 | Pancreatic carcinoma |
| 126364101 | 12636410 | 3 | Pancreatic carcinoma |
| 126364101 | 12636410 | 4 | Pancreatic carcinoma |
| 126364101 | 12636410 | 5 | Pancreatic carcinoma |
| 126364101 | 12636410 | 6 | Pancreatic carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126364101 | 12636410 | HO |
| 126364101 | 12636410 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126364101 | 12636410 | Febrile neutropenia | |
| 126364101 | 12636410 | Gait disturbance | |
| 126364101 | 12636410 | Neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |